"Harvard Business Review" released the list of "China's Top 100 CEOs in 2019", and Cai Dongchen, chairman of CSPC's board of directors, was shortlisted for the fourth consecutive year. According to relevant information, in the "2019 China's Top 100 CEO List", only 35 have been on the list for four years.
Since 2016, the Harvard Business Review first released the "China's Top 100 CEO List", it has used "persistent long-term companies can create lasting value for the company and shareholders" to evaluate the corporate value passed by the shortlisted companies. The two indicators are shareholder returns and changes in market value.
In the first three quarters of 2019, the total revenue of CSPC reached RMB 16.761 billion, a year-on-year increase of 27.5%. Among them, the brightest innovative drugs accounted for 56.83% of total revenue, accounting for half of the performance. In 2013, this figure was still 19.3%. CSPC, a "commodity manufacturer" that was criticized by certain fund managers 20 years ago, has now become a "national innovative company" and "the first pharmaceutical stock in the 50-year history of the Hang Seng Index" . An innovative "counter-attack" road confirms the success of CSPC's strategic transformation from APIs to high-end generic drugs to innovative drugs, and this transformation is undoubtedly the same as Cai Dongchen's "seeing the crisis when the company lives the best" and His insistence on innovation and transformation is inseparable.
Enbipu (chemical name: butylphthalide) is one of the representatives of CSPC's research and development achievements. After 11 years from CSPC's involvement in research and development to market sales, Cai Dongchen said, "When a strategy lasts for a period of time, When you do n’t see the results, there must be objections. Only when you stick to it, is it time to judge the success of the strategy. ”Strength and endurance have won a great picture. "The anti-tumor product portfolio has become the two major engines driving CSPC's performance, and CSPC has about 300 innovative drug product projects under development.
"Harvard Business Review" states: "In today's turbulent era, uncertainty has become a huge challenge for companies. The more turbulent the environment, the better it can reflect the management level of corporate leaders." "The Value of Baijia CEO It is not only that they have achieved excellent business performance, but more importantly, they have the determination and courage to face the crisis and challenges. "
The opponent is changing, the environment is changing, persistence is unchanged, innovation is constant, innovative products to continuously meet unmet clinical needs, and technological advancement to improve the quality of life are Cai Dongchen's perfect hope for CSPC.